<img src="/media/1098/mrbt_h_bk.svg" style="max-width:200px; margin-bottom:10px; display:block;" />MRBT Maintenance Drugs list
Maintenance drugs* that are subject to the new dispensing fee limits (effective January 1, 2021) generally fall into the following categories:
| Treatment categories | Drug examples** |
|---|---|
|
Stomach acid related disorders |
omeprazole, pantoprazole, ranitidine |
|
Diabetes |
metformin, gliclazide, linagliptin |
|
Common heart conditions |
ramipril, atorvastatin, metoprolol, rivaroxaban |
|
Hormone replacement therapy |
estradiol, conjugated estrogen, progesterone |
|
Osteoporosis |
alendronate, risedronate, raloxifene |
|
Depression and anxiety |
citalopram, amitriptyline, venlafaxine |
|
Bladder conditions |
oxybutynin, tolterodine |
|
Benign prostatic hyperplasia |
finasteride, tamsulosin |
|
Thyroid conditions |
levothyroxine, methimazole |
|
Gout therapy |
allopurinol, febuxostat, colchicine |
|
Chronic inflammatory conditions |
methotrexate, leflunomide, mesalazine |
|
Chronic lung conditions |
theophylline, montelukast, roflumilast |
*Solid-oral dosage forms (tablets and capsules) only; limits do not apply for non-solid oral medications (i.e. liquids, inhalers, compounds, injectables).
**This is not an exhaustive list of specific medications impacted in each category.
Dispensing fees for solid-oral drugs included on the Maintenance Drug list will be limited to five per year. All other solid-oral medications (tablets and capsules) used to treat chronic conditions will be limited to 13 dispensing fees per calendar year.